Trump revives presidential fitness test – will US students run a mile?
The test was administered in public middle and high schools in the United States from 1966 to 2013, when the Obama administration replaced it with the presidential youth fitness program – a similar physical assessment program, but with more focus on health education.
Health secretary Robert F Kennedy Jr – vaccine skeptic and key figure in the 'Make America Healthy Again' movement – will be in charge of administering the test.
In a statement reported by the AP, White House press secretary Karoline Leavitt said the president 'wants to ensure America's future generations are strong, healthy, and successful' and that young Americans 'have the opportunity to emphasize health, active lifestyles – creating a culture of strength and excellence for years to come'.
Below, what you need to know about the presidential fitness test.
Initiated by Dwight D Eisenhower in 1956, the test changed over the years, but generally consisted of five parts: a one-mile run, a shuttle run (moving as quickly as possible back and forth between two points), pull-ups or push-ups, sit-ups and the sit-and-reach (sitting on the ground with your legs outstretched and seeing how far down your legs your hands can reach).
According to the Harvard Health blog, the aim of the test was to 'assess cardiovascular fitness, upper-body and core strength, endurance, flexibility, and agility'.
The test derives from the Kraus-Weber test for muscular fitness, an assessment developed by Dr Hans Kraus and Dr Sonja Weber. The test was administered to thousands of students across the US and Europe.
Researchers found that European students performed significantly better than their American counterparts: 59.7% of US students failed at least one of the test's six exercises, compared to only 8.7% of European students.
According to a 1955 Sports Illustrated article, when Kraus presented his findings at the White House, President Eisenhower declared the problem 'a serious one'.
The president seemed less worried about children's health and wellbeing than he did their combat preparedness. According to the Department of Health and Human Service's 50-year-anniversary booklet about the test, 'his chief concern seemed to be the vulnerability to the red army'.
'Our growing softness, our increasing lack of physical fitness, is a menace to our security,' Eisenhower said.
It doesn't seem so. A 2025 report in the Journal of the American Medical Association found that from 2007 to 2023, trends had 'significantly worsened' for 'child mortality; chronic physical, developmental and mental health conditions; obesity; sleep health; early puberty; limitations in activity; and physical and emotional symptoms.'
And when it comes to competition with Europe, the US is faring even worse than it did before. Dr Christopher Forrest, one of the study's authors, told NPR that back in the 1960s, 'the chance that a child was going to die in the United States was the same as European nations'.
But from 2010 to 2023, 'kids in the United States were 80% more likely to die', than those in Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
I'm a hormone expert - this is why some people's sex drive goes through the roof when they take Mounjaro
A hormone expert has revealed a bizarre side-effect of weight loss jabs: they might send your sex drive soaring. Originally developed for diabetes, blockbuster drugs like Mounjaro are now famed for helping users shed weight rapidly by suppressing appetite. But it seems they may also be fuelling a surge in libido. Dr Shashi Prasad, a GP and expert in women's health, said while side-effects such as nausea and even organ damage have been widely reported, changes in sexual desire remain less understood. 'Sexual desire is such an important aspect of somebody's well-being and this is still a relatively new treatment,' she said. 'We are increasingly finding that it's having an impact on people's libido—and it's not all to do with self-esteem.' Dr Prasad explained that one possible reason for the effect is that body fat causes chronic, low-level inflammation—a key factor behind many obesity-related health issues, including reduced sex drive. Mounjaro works by mimicking a gut hormone called GLP-1, which is released after eating to regulate blood sugar and suppress hunger. Dr Prasad said Mounjaro may cause libido to sky rocket because of how it impacts a certain brain chemical Your browser does not support iframes. Your browser does not support iframes. As well as signalling the pancreas to produce more insulin, GLP-1 tricks the body into thinking it is full—stopping patients from overeating and triggering weight loss. More than 1.5 million patients in the UK are now paying for private Mounjaro prescriptions, as well as a similar drug called Wegovy. Some notice a change in their drinking habits, with many saying they no longer want alcohol. And this may give another clue to the apparent libido-boosting effect of the jabs, according to Dr Prasad. She explains that whilst alcohol affects the part of the brain that controls inhibition—explaining why people often feel less anxious and more confident after a drink—it can dampen sex drive. 'Alcohol is a very addiction-based behaviour,' Dr Prasad explained. 'It has a suppressive effect on our emotions, releasing inhibition which can make some people more sexually inclined. 'But, sexual desire is more than that. Remember, alcohol is a depressant, so whilst you may feel more confident after a drink, physiologically alcohol actually suppresses sexual desire.' A change to body image and the resulting boost in confidence does also play a part, she adds. Researcher shows that women between the ages of 20 and 59 who had sex less than once a week were at a 70 per cent increased risk of death within five years Your browser does not support iframes. Your browser does not support iframes. 'We know that body image, self-esteem and confidence definitely play a huge role in sexual desire—and this psychological boost associated with weight loss is a very big element.' But some users have reported the opposite effect—finding they want to have sex less frequently. This may be because the drugs suppress the production of dopamine—the feel-good chemical the brain produces in response to pleasurable experiences. 'Our brains produce dopamine in response to anything that brings us pleasure, whether that's food, alcohol, cigarettes, socialising or sex,' says Dr Alexis Bailey, a neuropharmacologist at City St George's university in London. 'The leading theory is that GLP-1 injections helps dampen these dopamine surges.' According to Dr Prasad, this can cause a significant drop in sex drive, resulting in users feeling more confident in their new bodies but not wanting to have sex. She added that losing a lot of weight over a short period of time can also affect hormone balance, as can a restricted diet, by reducing levels of sex hormones testosterone and estrogen that are crucial for sexual desire. Dr Prasad encouraged users to have a discussion with their doctors if they are concerned about their sex drive. She said: 'This should help you get to the root cause of the problem. A drop in sex drive could simply be the result of fatigue caused by being in a calorie deficit. 'Or it could mean that your dose is too high and the drug is significantly affecting your nervous system and dopamine production.' Either way, Dr Prasad said: 'Make sure you're eating a balanced, nutrient-dense diet with plenty of fibre and protein and exercising regularly—this will trigger the release of endorphins and may improve sexual desire.' She is now urging health officials to conduct more research into this aspect of the drug, and encouraging more open and honest conversations about sex and weight loss. 'Sexual desire is such an important aspect of someone's identity—it is very important to flag this up and encourage patients to have a discussion with their doctor.' Her advice comes amid growing concern over a global sex crisis—or rather, lack of sex crisis. One recent survey revealed more than a quarter of people living in the UK are having less sex than they used to, with one in six admitting they haven't got frisky the entire year. Last month, researchers at the University of Manchester, also revealed women who have sex at least once a week are the happiest in their relationships. Their study showed that 85 per cent of women who had sex once a week described themselves as 'sexually satisfied'. In contrast, only 17 per cent of women who had sex less than once a month reported the same level of relationship bliss. Sex and intimacy have been linked to several health benefits, including improving the condition of your heart, reducing stress and even boosting mental health.
Medical News Today
3 hours ago
- Medical News Today
Might a combination of 2 cancer drugs help treat Alzheimer's disease?
Researchers are actively seeking treatments or a cure for Alzheimer's diseaseOne current research avenue is to look at currently-approved medications that are used for other diseases, an approach that is called drug repurposing. A new study has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Researchers all over the world are actively seeking treatments or a cure for Alzheimer's disease — a form of dementia currently impacting about 32 million people globally. The medications used right now for Alzheimer's disease are designed to only help treat symptoms and slow disease progression. One avenue scientists are taking in an effort to find treatments for Alzheimer's disease is by looking at currently-approved medications that are used for other diseases, an approach called drug repurposing. 'The idea of drug repurposing or identifying new uses for existing drugs, can speed up the drug discovery process because the compounds already have been tested for toxicity and adverse events,' Marina Sirota, PhD, professor and interim director of the University of California — San Francisco Bakar Computational Health Sciences Institute explained to Medical News Today.'Alzheimer's disease is a complex disease, which is very difficult to treat so we need to use all the tools possible to speed up drug discovery and help patients,' said SirotaSirota is the co-senior author of a new study recently published in the journal Cellthat has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Focusing on cancer drugs letrozole and irinotecanFor this study, researchers began by using past studies to assess how Alzheimer's disease changed gene expression in brain cells, mainly neurons and glia. 'Glia cells are non-neuronal cells that provide support and protection to neurons in the nervous system,' Sirota explained. 'By targeting both neuronal cells and non-neuronal cells (glia) we hope to be able to more comprehensively target disease pathophysiology.' From there, scientists then took the gene expression signatures they found and used a database called the ConnectivityMap, allowing them to examine thousands of drugs to find ones that reversed the Alzheimer's disease gene expression signature.'We started with a set of 1,300 drugs and narrowed it down to the combination of letrozole and irinotecan through data driven analysis using both molecular and clinical data,' Sirota said.'We first identified compounds that reversed the cell type specific disease signatures back to normal based on the gene expression profiles. We then further filtered the list to the candidates that affect several cell types,' she explained.'Then we wanted to see whether patients who are on those drugs already have a lower risk of Alzheimer's disease by querying electronic medical records across the UC system,' she continued. 'This has allowed us to narrow our list down to a handful of drugs and focus on this combination.' The analysis of electronic medical records did indeed show that both drugs were associated with a significantly lower risk of Alzheimer's disease, confirming the of cancer drugs reverses brain cell damage, reduces protein build-up in mouse modelNext, researchers decided to test the combination of letrozole — used to treat breast cancer — and irinotecan — used to treat colorectal and lung cancer — in a mouse model of aggressive Alzheimer's disease. At the study's conclusion, Sirota and her team found that the drug combination overturned multiple aspects of Alzheimer's disease in the mouse model, including undoing the gene expression signature changes in the neurons and glia caused by the disease. Additionally, researchers found the combination cancer drugs helped reduce the amount of amyloid-beta and tau proteins in the brain, which are known hallmarks of Alzheimer's disease. 'This tells us that multiple levels of evidence — molecular data, clinical information and mouse model experiments are all aligning to tell us that these compounds might be helpful for Alzheimer's disease patients,' Sirota further noted that:'While we don't know the exact mechanism of how these drugs work to treat Alzheimer's disease, we know that irinotecan is a chemotherapy drug that works by inhibiting the enzyme DNA topoisomerase I, specifically targeting the S and G2 phases of the cell cycle. Letrozole's mechanism of action involves inhibiting the enzyme aromatase, which is crucial in the biosynthesis of estrogen.''However, we don't know whether it is the main aforementioned mechanisms or off-target effects of these drugs which might help Alzheimer's disease patients,' Sirota cautioned. 'Additional experiments need to be carried out to better understand how these two drugs might work together to combat Alzheimer's disease in patients.'Using 'big data' and inventive approaches to find potential Alzheimer's drug targetsMNT had the opportunity to speak with John Dickson, MD, PhD, a neurologist at Massachusetts General Hospital, about this research. 'This is an interesting and innovative paper that uses 'big data' to aid in identifying potential drug targets to treat Alzheimer's disease and then tests candidates in a preclinical model of Alzheimer's disease,' Dickson, who was not involved in this research, said.'Combining the use of transcriptomic data from brain tissue from Alzheimer's disease patients, drug perturbation studies in cell lines, and patient data from electronic medical records was an inventive approach to identifying and narrowing down potential drug targets,' he Dickson's view, 'the decision to use a dual-therapy approach and plan to target multiple cell types with this strategy was also innovative.''The combination of drugs showed beneficial effects on the memory testing and neuropathological findings in a mouse model of Alzheimer's disease. In addition to identifying two potential candidate therapies for Alzheimer's disease, this paper also provides an experimental paradigm for identifying new drugs to treat a variety of conditions,' he look at repurposing existing drugs for Alzheimer's treatment? MNT also talked to Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA, about this study, who said it is refreshing to see data that supports improving memory loss through a novel mechanism that is not related to current therapies that work on brain acetylcholine, N-methyl-D-aspartate (NMDA), or amyloid.'This study's design is smart and the data is captivating,' Segil, who likewise was not involved in the research, added. 'Repurposing medications already being used has been extremely rewarding in neurologists and I truly hope something grows out of this research.' And Peter Gliebus, MD, neurologist and director of cognitive and behavioral neurology at Marcus Neuroscience Institute, part of Baptist Health South Florida, also not involved in the research, commented to MNT that this was a promising and exciting study, and said that repurposing existing drugs offers several advantages. 'Faster development since these drugs already have established safety profiles, which reduces the time and cost required for clinical trials,' Gliebus noted.'Cost-effectiveness [is achieved] by avoiding the high expenses associated with developing new drugs from scratch. And [this approach has] a broader impact, as many existing drugs may have unexplored mechanisms that could address complex Alzheimer's disease pathologies, such as neuroinflammation, synaptic dysfunction, and metabolic deficits.''Given the high failure rate of Alzheimer's drug trials, repurposing provides a practical and efficient pathway to identify effective treatments,' the neurologist concluded.
BBC News
3 hours ago
- BBC News
School grief lessons hailed by Norfolk charity Nelson's Journey
Adding bereavement education to primary school curriculums has been hailed as an important change that could bring long-term societal update to government guidance on relationships, sex and health education (RSHE) has advised that from September 2026 children should be taught about dealing with death before leaving primary guidance says pupils should be reassured that "grief is a natural response to bereavement" and that "everyone grieves differently".Simon Wright, chief executive of Norfolk-based bereavement charity Nelson's Journey, said: "We know that unsupported grief for children can have quite devastating consequences that can stick with children for some time." The RSHE change formalises an issue which is already addressed by some schools, with Nelson's Journey among the organisations to offer training for teachers and other professionals. Mr Wright said his staff were "very pleased" about the addition as many people do not realise how prevalent the issue said that research showed one in 29 school age children experienced the death of a sibling or parent and that the Little Plumstead-based charity received around 700 referrals for young people every Wright, the former MP for Norwich South, continued: "Developing that understanding of grief for all young people is incredibly important, both for those young people who have experienced death but also for all children to understand their relationship with others who may be grieving."So we feel this is an announcement that could have a really positive impact."Some schools in Norfolk already do include discussions about death and we're always really keen to talk to teachers who do that and discuss the approaches they can take with different aged children." 'Children are inquisitive' Jay Harrison works as part of the bereavement service offered by the mental health charity Norfolk and Waveney Mind - and has also praised the change as positive news."Kids are cleverer than we give them credit for," said Mr Harrison. "They are inquisitive, so they are going to have questions about what happens."I think it's our duty as adults and responsible people who are maybe a little bit more in touch with our emotions and our feelings, to be able to impart that knowledge on young people and realistically create a more resilient community moving forward." Shannon O'Sullivan, headteacher at Thomas Bullock Primary School in Shipdham, has also welcomed the addition from the Department for to BBC Radio Norfolk, she said: "Preparing children for these real-life events and normalising that we have an emotional response to loss will really help children to understand that feeling worried or low is normal and doesn't automatically mean that there are wider issues."We as adults understand that grief is linear, it's a journey and we give ourselves time – and sometimes not enough time – to have those periods of emotions."So teaching children that it is okay to express yourself and teaching them the language around that is going to be the building of understanding that helps them to have those emotions." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
